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Cognitive dysfunction is present in up to 70% of patients with multiple sclerosis (MS) and 
has been reported at all stages and in all subtypes of the disease. These deficits have 
been reported across a variety of cognitive domains, but are generally under-recognized 
and incompletely evaluated in routine clinical practice. The aim of this study was to 
investigate the spectrum of cognitive impairment in patients with MS presenting to a 
specialist MS clinic using the Cambridge Neuropsychological Test Automated Battery 
(CANTAB), administered on a touchscreen platform. Ninety MS patients completed 
computerized CANTAB tasks assessing working memory, executive function, process-
ing speed, attention, and episodic memory. Scores were adjusted for age, sex, and level 
of education and classified as normal or impaired based on comparison with a large nor-
mative data pool. We also investigated the impact of clinical and demographic variables 
which could potentially influence cognitive performance including patient educational 
level (a proxy for cognitive reserve), disease status (duration, course, and severity of MS), 
and depression. CANTAB testing detected cognitive impairment in 40 patients (44% of 
the sample). The most frequently impaired domain was executive function, present in 
55% of cognitively impaired individuals. Disease duration and severity were significantly 
associated with performance across various cognitive domains. Patients with depressive 
symptoms were also more likely to exhibit impaired processing speed. Results from 
this study confirm that cognitive impairment is common and occurs across a range of 
domains among MS patients attending routine clinical visits. CANTAB tasks provide a 
sensitive and practical approach to cognitive testing in MS patients as part of a holistic 
patient assessment.
Keywords: multiple sclerosis, cognition, cambridge neuropsychological Test automated Battery, computerized 
testing, neuropsychological assessment
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inTrODUcTiOn
Cognitive dysfunction is present in up to 70% of patients with 
multiple sclerosis (MS) and has been reported at all stages and in 
all subtypes of the disease (1–3). These deficits have been reported 
across a variety of cognitive domains and are thought to arise as a 
result of the diffuse white and gray matter damage associated with 
MS (4–6). Cognitive dysfunction is a leading cause of disability 
in MS and is associated with unemployment (7, 8), increased car-
egiver burden (9, 10), and poor quality of life (11–13). However, 
cognitive impairment is often under-recognized and incompletely 
evaluated in patients with MS (6).
Cognitive deterioration is often overlooked, in part, due 
to a lack of tools suitable for use in routine clinical practice. 
Cognitive batteries are typically time-consuming, require special-
ist resources and a trained rater to administer and interpret the 
results of these tests. While a number of cognitive batteries have 
been developed specifically for use in patients with MS, including 
the Brief Repeatable Battery of Neuropsychological tests (BRB-
N) (14), the Minimal Assessment of Cognitive Function in MS 
(15), and the Brief International Cognitive Assessment for MS 
(BICAMS) (16), these retain many of these practical limitations. 
There is a need for sensitive as well as time and resource-efficient 
tests for detecting cognitive impairment as part of routine holistic 
patient assessment in MS clinics.
The Cambridge Neuropsychological Test Automated Battery 
(CANTAB) consists of a number of computerized tests that can 
be administered via touchscreen platforms to assess discrete 
cognitive subdomains (17, 18). These have been developed and 
validated over the past 30 years and offer potential benefits over 
conventional paper-and-pencil based cognitive tests (19). These 
touchscreen tasks ensure accurate response scoring and provide 
precise assessment of reaction-time based measures. Automated 
instructions are available in a range of languages and tasks can 
be largely self-administered by patients, requiring no technical 
knowledge or prior familiarity. Automatic scoring and compari-
son to normative data also provides clinicians with an indication 
of a patient’s level of cognitive performance relative to individuals 
of a similar age, sex, and level of education in the general popula-
tion. CANTAB tasks have demonstrated sensitivity to cognitive 
dysfunction and have been widely used across a range of clinical 
groups (20–23), including patients with MS (24–26). The aim of 
this study was to investigate domain-specific cognitive impair-
ment in patients with MS using CANTAB in routine clinical care. 
We also sought to examine whether patient educational level [a 
proxy for cognitive reserve (27)], disease status (duration, course, 




105 consecutive patients attending a specialist MS clinic at 
the Anne Rowling Regenerative Neurology Clinic, University 
of Edinburgh, between March 2014 and October 2014 were 
offered the opportunity to complete a series of cognitive tests 
as part of their routine holistic clinical assessment. All patients 
included in the current study met McDonald criteria for MS 
(28). None of the patients were in acute relapse at the time 
of the assessment. Electronic patient records, clinical case 
notes, and patient interviews were reviewed to determine 
patient demographics, disease course, duration, and Expanded 
Disability Status Scale (EDSS) (29) score (reflecting the degree 
of physical disability). Patients were also screened for depres-
sion using a touchscreen version of the 15-item Geriatric 
Depression Scale (GDS) (30).
cognitive Testing
Three automated CANTAB neuropsychological tests were 
administered using a touchscreen tablet computer (iPad Air, 
Apple Inc.). The user-friendly touchscreen platform used for 
patient testing required no prior neuropsychological training for 
administration. Each task incorporated an automated computer 
voiceover providing instructions to patients. The cognitive assess-
ment battery took approximately 15 minutes to complete:
 1. Match to Sample: assesses processing speed and attention
 2. Paired Associates Learning: assesses visuospatial episodic 
memory
 3. Spatial Working Memory: assesses working memory and 
executive function (specifically strategic planning)
Upon completion of cognitive testing, patient raw scores for 
each cognitive domain were internally processed by the software 
to create z-scores. These z-scores were standardized for age, 
sex, and education status using data from an inbuilt normative 
database collected from healthy adults aged 18–90 years. Based 
on these z-scores, cognitive performance levels were categorized 
from “superior” (z-score > 1.5) to “very poor” (z-score < −2), 
though “average” (z-score  ≥  −1) was the highest possible 
category for some tests. Patients scoring “poor” or “very poor” 
(z-score < −1.5) in a cognitive domain were considered to be 
impaired relative to their age, sex, and education-matched peers.
statistical analyses
Data were analyzed using SPSS statistical software (IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY, USA: IBM 
Corp.). Chi-square test and Fisher’s exact test were used to exam-
ine group differences in the proportion of patients demonstrating 
cognitive impairment in each cognitive domain based on level of 
education, depression, and MS disease course. Spearman’s rank-
order correlation test was used to examine associations between 
disease duration and severity with cognitive performance, based 
on the aforementioned z-score derived performance categories. 
All analyses were two-tailed, p < 0.05 was considered statistically 
significant.
ethical approval
As cognitive assessments were performed as part of routine 
clinical evaluation of patients, and clinical data were handled in 
an anonymized fashion, the Local Research Ethics Committee 
deemed that specific ethical approval was not required for this 
study.
FigUre 1 | Patient recruitment flowchart.
TaBle 1 | Patient clinical and demographic characteristics.
n (%)
Sex Male 22 (24%)
Female 68 (76%)
Level of education Left before age 16 9 (10%)
Left age 16–18 41 (46%)
Left after age 18 40 (44%)
Multiple sclerosis disease 
course
Relapsing–remitting 65 (72%)
Primary progressive 10 (11%)
Secondary progressive 15 (17%)
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resUlTs
Patient characteristics
Ninety MS patients completed the CANTAB assessments (mean 
age 44.5 ± 10.9 years, range: 22–70 years). The average duration 
of disease was 11.4 ± 9.0 years (range: 0–39 years). The average 
EDSS score was 3.6 ± 2.4 (range: 0–7.5). Further demographic 
and clinical characteristics of the patients included in this 
study are presented in Table 1. Fifteen patients were excluded 
(Figure  1), though further details on the MS patients that 
did not complete the CANTAB assessments (n = 9) were not 
recorded.
cognitive impairment in Ms
CANTAB tests detected cognitive impairment in at least one 
cognitive domain among 40 (44%) of the patients. Twenty-three 
percent of cases demonstrated impairment across multiple 
cognitive domains (Figure 2). Executive function was the most 
commonly impaired domain (Figure  3A) and was present in 
55% of patients who exhibited impairment in at least one cogni-
tive domain (Figure 3B).
association With education
For the purposes of the normative comparisons, the education 
level of patients was recorded into one of three categories; (1) 
those who left school before the age of 16, (2) those who left 
between ages 16 and 18, and (3) those who completed educa-
tion after 18 years of age. As there were only a small number of 
individuals who had only completed up to 16 years of education 
(n = 9), we merged categories one and two for the purposes of 
examining whether cognitive impairment was associated with 
level of education across the sample. This was intended to serve as 
a proxy for cognitive reserve, given that higher levels of education 
are thought to be protective against cognitive decline in MS. We 
therefore conducted our analyses based on those individuals with 
≤18 (n = 50) or >18 years of education (n = 40). There were no 
significant differences in the proportion of patients with cognitive 
impairment in any cognitive domain between these two groups 
(all p ≥ 0.22).
association With Ms Disease Duration, 
severity, and course
Spearman’s rank-order correlations were performed to exam-
ine the associations between disease duration and severity 
with cognitive performance (Table 2). A longer disease dura-
tion was associated with poorer performance on measures of 
processing speed and attention. More severe physical disabil-
ity (as assessed using the EDSS) was significantly associated 
with poorer performance on measures of working memory, 
executive function, processing speed, and attention. A higher 
proportion of patients with primary progressive (20%) and 
secondary progressive MS (13%) exhibited impaired atten-
tion compared to those with relapsing–remitting MS (3%), 
though this did not reach statistical significance (p = 0.056). 
There were no other statistically significant differences in the 
proportion of patients with impairment in any of the cogni-
tive domains between the different MS disease courses (all 
p ≥ 0.38).
association With Depression
Clinically significant depressive symptoms (GDS  ≥  5) were 
identified in 33 (37%) patients. One patient did not complete the 
GDS questionnaire and was, therefore, excluded from this analy-
sis. When analyzed using Fisher’s exact test, a higher proportion 
of patients with depression exhibited impaired processing speed 
compared to non-depressed patients (p = 0.013). There were no 
significant differences in the proportion of cognitively impaired 
individuals between the depressed and non-depressed patients 
in any other domains (all p ≥ 0.061).
DiscUssiOn
summary of results
Cognitive impairment was identified using CANTAB in 44% 
of patients attending routine appointments at a specialist MS 
clinic. This figure is comparable to the proportion of MS patients 
affected by cognitive impairment reported in other studies 
based on longer and more resource-intensive cognitive batteries 
(31–33). Executive function (specifically strategic planning) was 
the domain most commonly impaired among patients. There 
was also evidence that both disease duration and degree of 
physical disability may be associated with the severity of cognitive 
AB
FigUre 3 | (a) Percentage of multiple sclerosis (MS) patients with impairment in specific cognitive domains across the whole sample (n = 90). (B) Percentage of 
MS patients with impairment in specific cognitive domains among the impaired group (n = 40).
FigUre 2 | Percentage of multiple sclerosis patients with impairment in different cognitive domains.
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dysfunction observed in patients with MS. These results dem-
onstrate that CANTAB tasks can be used to provide a brief yet 
sensitive and comprehensive assessment of cognition in patients 
with MS as part of their routine clinical care.
relationship to clinical and Demographic 
Variables
Consistent with previous research (34), longer disease duration 
was associated with poorer processing speed and attention. 
TaBle 2 | Correlations between disease duration, severity, and cognitive 
performance.
Disease duration (years) Disease severity 
(expanded Disability 
status scale score)
rs p-Value rs p-Value
Working memory −0.118 0.269 −0.215 0.042
Executive function −0.083 0.436 −0.224 0.034
Processing speed −0.218 0.039 −0.298 0.004
Attention −0.206 0.051 −0.263 0.012
Episodic memory −0.073 0.492 −0.132 0.216
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Higher EDSS scores were significantly associated with poorer 
working memory, executive function, processing speed, and 
attention. The EDSS is rated by a neurologist and is heavily 
reliant on walking as the main factor for quantifying disability 
(29). However, this measure has consistently been reported to be 
among the strongest correlates of cognitive impairment in MS 
(35), suggesting similar processes may drive both physical and 
cognitive disability in patients. We did not identify any statisti-
cally significant differences between the different MS disease 
subtypes in the proportion of patients with impairment across 
any of the cognitive domains. This is likely due to a lack of power 
to detect group differences in cognitive performance due to the 
relatively small number of patients with progressive forms of 
illness. Larger studies have reported that those MS patients with 
a progressive disease course exhibit more severe and widespread 
deficits in cognitive performance compared to those with a relaps-
ing–remitting course (36, 37). This is perhaps unsurprising given 
that relapsing–remitting MS is characterized by bouts of inflam-
mation and periods of recovery and remyelination whereas in the 
progressive phase, episodes of inflammation and demyelination 
become more infrequent with a shift toward neurodegeneration 
and sustained damage (38).
Cognitive reserve has been identified as a potential buffer 
against cognitive impairment with intellectually enriching 
experiences, such as high levels of education, thought to protect 
against MS-related cognitive decline (27, 39). We failed to iden-
tify any significant differences in the proportion of MS patients 
with cognitive impairment between those who left education 
prior to age 18 compared to those who went on to further educa-
tion, though this may be attributable to a lack of variability in 
the data based on these categories. High GDS scores (indicative 
of depression) were associated with impaired processing speed, 
though it is difficult to determine the direction of causality in 
this cross-sectional association. Patients with major depressive 
disorder display impaired cognitive performance on CANTAB 
tests (23); however, cognitive dysfunction has also been shown to 
adversely affect social and occupational functioning and quality 
of life in patients with MS (7, 11, 12), which is also likely to drive 
depressive symptoms.
clinical implications
Multiple sclerosis is a disease characterized by considerable patient 
heterogeneity in clinical presentation, lesion profile, and degree 
of cognitive dysfunction (4, 40, 41). Cognitive assessment should 
therefore be an important part of routine clinical care for exam-
ining the impact and progression of MS. Detection of cognitive 
impairment in MS is important, as it allows appropriate support 
to be instituted, and practical measures to overcome functional 
deficits to be implemented. Deficits are most commonly reported 
in processing speed, episodic memory, attention, and executive 
function among patients with MS, while other domains such as 
language abilities typically remain intact (4, 6). The results of this 
study indicate that CANTAB tasks are sensitive to impairment in 
each of these domains most frequently affected in MS. Though 
there are currently no regulatory approved pharmacological 
treatments for the amelioration of cognitive dysfunction in MS 
(42, 43), there is emerging evidence that cognitive rehabilitation 
interventions and physical exercise may exert pro-cognitive 
effects in this population and may be useful in limiting further 
cognitive decline (44–48).
strengths and limitations
Cognition was assessed using a brief, computerized cognitive test 
battery that has been developed and validated by over 30 years 
of research (17–19), and which has previously been shown to 
be sensitive to cognitive deficits in patients with MS (24–26). 
Computerized cognitive testing helps to overcome many of the 
practical limitations of existing paper-and-pencil- based cogni-
tive tasks in routine clinical care and has been shown to be well-
tolerated by patients, even among very elderly individuals (49). 
Though the CANTAB battery used in this project was designed 
to assess the cognitive domains most frequently impaired in MS, 
there is an emerging literature suggesting that other cognitive 
processes, such as social cognition (5, 50), may also be adversely 
affected in this population. However, the “real world” impact of 
deficits in these abilities remain poorly understood and warrant 
further investigation prior to inclusion into routine cognitive 
assessment in clinical care (51).
Nine patients did not complete the CANTAB tests; however, 
no further clinical or demographic information was recorded for 
these individuals. It is therefore unclear whether they are missing 
at random or whether this introduces some bias into the current 
analyses. Data on the use of disease modifying therapies were also 
not collected at the time of the assessments, though there is currently 
limited evidence that these drugs have an impact on cognition (43). 
An additional limitation of the current study is that information 
relating to fatigue and daytime sleepiness was not recorded. These 
are common symptoms among patients with MS and may be associ-
ated with poor cognitive performance (4, 52). Depressive symptoms 
were assessed using the GDS, though originally developed for use 
in older adults, the content is generic and not age-specific (30). 
Published studies in both clinical and non-clinical populations have 
demonstrated that this is a sensitive and reliable tool for assessing 
depressive symptoms in adults of all ages (53–55).
conclusion
Results from this study confirm that cognitive impairment is 
common among patients with MS, that it occurs across a range 
of domains, and is associated with disease-related variables. 
CANTAB tasks provide a sensitive and practical tool for cogni-
tive testing in MS patients as part of a holistic patient assessment. 
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These computerized touch screen tests help to overcome many of 
the challenges faced when assessing cognition in clinical practice.
eThics sTaTeMenT
As cognitive assessments were performed as part of routine 
clinical evaluation of patients, and clinical data was handled in 
an anonymized fashion, the Local Research Ethics Committee 
deemed that specific ethical approval was not required for this 
study.
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